Rolf Larsson

Publikationer

Senaste publikationer

• Exploratory insights from the immuno-oncology hollow fiber assay (2024)
• Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs (2024)
• Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients (2023)
• Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases (2023)
• Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death (2023)

Alla publikationer

Artiklar

• Exploratory insights from the immuno-oncology hollow fiber assay (2024)
• Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs (2024)
• Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients (2023)
• Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases (2023)
• Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death (2023)
• Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome (2022)
• Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells (2022)
• Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival (2022)
• Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma (2022)
• Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model (2022)
• Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes (2021)
• Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients (2021)
• DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML) (2021)
• A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer (2021)
• Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway (2020)
• Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide (2020)
• Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. (2020)
• Antibacterial pyrrolidinyl and piperidinyl substituted 2,4-diacetylphloroglucinols from Pseudomonas protegens UP46 (2020)
• Isopedopeptins A-H (2020)
• Descriptive Proteome Analysis to Investigate Context-Dependent Treatment Responses to OXPHOS Inhibition in Colon Carcinoma Cells Grown as Monolayer and Multicellular Tumor Spheroids (2020)
• Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition (2019)
• Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity (2019)
• Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors (2018)
• Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors (2018)
• Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy (2017)
• The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation (2017)
• Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB) (2017)
• Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. (2017)
• Mass spectrometry based metabolomics for in vitro systems pharmacology (2017)
• Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin (2017)
• Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity (2017)
• Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism (2017)
• Targeting tumor cells based on Phosphodiesterase 3A expression (2017)
• Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype (2017)
• In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia (2017)
• Melflufen (2017)
• Characterizing the effects of epigenetic regulation in assays using peripheral blood mononuclear cells from patients with inflammatory diseases (2016)
• Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy (2016)
• Preclinical activity of melflufen (J1) in ovarian cancer (2016)
• In vitro and in vivo activity of melflufen (J1) in lymphoma (2016)
• Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects (2016)
• Iron chelators target both proliferating and quiescent cancer cells (2016)
• Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition (2016)
• Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids (2016)
• Detection of cell aggregation and altered cell viability by automated label-free video microscopy (2015)
• Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs (2015)
• Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei (2015)
• Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia (2015)
• In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index (2015)
• Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs (2015)
• The Mutational Landscape in Pediatric Acute Lymphoblastic Leukemia Deciphered by Whole Genome Sequencing (2015)
• The anticancer activity of the DUB inhibitor b-AP15 is associated with accumulation of proteasome bound ubiquitin and oxidative stress (2015)
• Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation (2015)
• DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia (2015)
• Perfusion Of Porcine Kidneys With Macromolecular Heparin Ameliorates Early Ischemia Reperfusion Injury (2015)
• Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics (2015)
• Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer (2015)
• Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter (2014)
• Label free high throughput screening for apoptosis inducing chemicals using time-lapse microscopy signal processing (2014)
• Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress (2014)
• AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia (2014)
• Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia (2014)
• Identification of an inhibitor of the ubiquitin-proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function (2014)
• Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy (2014)
• Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion (2014)
• A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses (2014)
• Drug repositioning from bench to bedside (2014)
• Modifying the vessel walls in porcine kidneys during machine perfusion (2014)
• A spheroid-based screen identifies mitochondrial targeting as a promising strategy for cancer treatment and drug repositioning (2014)
• Beneficial Effects of Coating Alginate Microcapsules with Macromolecular Heparin Conjugates-In Vitro and In Vivo Study (2014)
• Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome (2014)
• The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death (2014)
• Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments (2014)
• Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments (2014)
• Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer (2013)
• Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system (2013)
• Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance (2013)
• Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells (2013)
• Attachment of macromolecular heparin conjugate to gelatin scaffolds improves endothelial cell infiltration (2013)
• Evaluation of the blood compatibility of materials, cells and tissues (2013)
• Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia (2013)
• Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer (2013)
• Effects of hypoxia on human cancer cell line chemosensitivity (2013)
• The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo (2013)
• Association of interferon stimulated genes and IRF9 upregulation with drug resistance in multicellular spheroids and monolayer cells upon crowding (2013)
• Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo (2013)
• Conducting Nanocellulose Polypyrrole Membranes Intended for Hemodialysis (2012)
• Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma (2012)
• The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia (2012)
• Haemocompatibility and ion exchange capability of nanocellulose polypyrrole membranes intended for blood purification (2012)
• In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues (2012)
• The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy (2012)
• Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system (2012)
• Brunn (2011)
• Inhibition of proteasome deubiquitinating activity as a new cancer therapy (2011)
• Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids (2011)
• Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment (2011)
• Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia (2011)
• Novel activity of acriflavine against colorectal cancer tumor cells (2011)
• In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia (2011)
• Antimicrobial and antineoplastic activities of Agelasine analogs modified in the purine 2-position (2011)
• Aminopeptidase N (CD13) as a target for cancer chemotherapy (2011)
• Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets (2010)
• Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia (2010)
• The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing (2010)
• Alpha Terpineol (2010)
• Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index (2010)
• Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells (2010)
• High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation (2010)
• Safety and efficacy of NAD depleting cancer drugs (2010)
• The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan (2010)
• Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system (2009)
• Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin (2009)
• Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters (2009)
• Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism (2009)
• Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines (2009)
• Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients (2009)
• Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids (2009)
• In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia (2009)
• ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action (2009)
• In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies (2009)
• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1 (2008)
• A new method for incorporating functional heparin onto the surface of islets of Langerhans (2008)
• Gene expression signature-based chemcial genomics and activity pattern in a panel of tumour cell lines propose linalyl acetate as a protein kinase/NF-κB inhibitor (2008)
• Anti colon cancer components from lebanese sage (Salvia libanotica) essential oil (2008)
• Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia (2008)
• The fluorometric microculture cytotoxicity assay (2008)
• Towards high-throughput single cell/clone cultivation and analysis (2008)
• Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis (2008)
• Surface-adsorbed fibrinogen and fibrin may activate the contact activation system (2008)
• The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro (2008)
• In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency (2007)
• STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines (2007)
• Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity (2007)
• R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells (2007)
• Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro (2007)
• Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells (2007)
• Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia (2007)
• Image-based screening for the identification of novel proteasome inhibitors (2007)
• The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications (2007)
• Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs (2007)
• Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients (2007)
• The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo (2007)
• Effects on blood compatibility in vitro by combining a direct P2Y(12) receptor inhibitor and heparin coating of stents (2006)
• Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model (2006)
• CHS 828 kill tumour cells by inhibiting the nuclear factor-kappa B translocation but unlikely through down-regulation of proteasome (2006)
• Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines (2006)
• Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram (2006)
• p53 is involved in clearance of ionizing radiation-induced RAD51 foci in a human colon cancer cell line (2006)
• (+)-agelasine D (2006)
• Improved blood compatibility of a stent graft by combining heparin coating and abciximab. (2005)
• Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. (2005)
• Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia (2005)
• In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia (2005)
• Screening for apoptosis--classical and emerging techniques. (2005)
• Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. (2005)
• Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles (2005)
• Bioactive heparin immobilized onto microfluidic channels in poly(dimethylsiloxane) results in hydrophilic surface properties, (2005)
• Bioactive heparin immobilized onto microfluidic channels in poly(dimethylsiloxane) results in hydrophilic surface properties. (2005)
• Functionality and stability of heparin immobilized onto poly(dimethylsiloxane) (2005)
• Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer. (2005)
• In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia. (2005)
• In vitro drug resistance in B cell chronic lymphocytic leukemia (2005)
• Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. (2004)
• Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. (2004)
• Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguadine CHS 828 (2004)
• Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo. (2004)
• Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. (2004)
• Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. (2004)
• Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828 (2004)
• Multiparametric evaluation of apoptosis (2004)
• Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. (2004)
• Cytotoxic cyclotides from Viola tricolor (2004)
• VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia (2004)
• Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia (2003)
• Antitumor activity of the alkylating oligopeptides J1(L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2(L-prolyl-m-L-fluorophenylalanine ethyl ester):comparison with melphalan. (2003)
• Structure activity relationship for alkylating dipeptide nitrogen mustard derivatives (2003)
• Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-melphalanyl-p-L-fluorophenylalanine ethyl ester) (2003)
• Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. (2003)
• Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. (2003)
• Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells (2003)
• Characterization of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance (2003)
• Overview of the clinical efficacy of investigational anticancer drugs. (2003)
• C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. (2002)
• Selection of chemotherapy by ex vivo assessment of tumor sensitivity tocytotoxic drugs: results of a clinical trial. (2002)
• Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. (2002)
• Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients. (2002)
• Assessment of drug activity and proliferation ex vivo for prediction ofoutcome in aggressive non-Hodgkin's lymphomas. (2002)
• DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. (2002)
• In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia (2002)
• Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells. (2002)
• A phase I study of CHS 828 in patients with solid tumor malignancy. (2002)
• Coagulation, fibrinolysis and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting using a new heparin-coated surface (2002)
• Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface (2002)
• Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga (2002)
• Cyclotides (2002)
• Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. (2002)
• Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1 (2002)
• The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro from cytotoxic synergy to complete inhibition of apoptosis. (2002)
• Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets (2002)
• CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogeneic drugs. (2002)
• In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin´s lymphoma. (2002)
• Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. (2001)
• A new in vitro model for the study of pig-to human vascular hyperacute rejection. (2001)
• Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. (2001)
• Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis (guanylhydrazone). (2001)
• A hollow fiber model for in vitro studies of cytotoxic compounds: activityof the cyanoguanidine CHS 828. (2001)
• Model for time dependency of the cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. (2001)
• Contact between a polymer and whole blood: sequence of events leading to thrombin generation. (2001)
• Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells (2001)
• In vivo activity of CHS 828 on hollow-fibre cultures of primary humantumour cells from patients. (2001)
• Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. (2001)
• Temporal effects of the novel antitumour pyridyl cyanoguanidine CHS 828, on human lymphoma cells. (2001)
• Characteristics of etoposide induced apoptopic cell death in the U-937 human lymphoma cell line. (2001)
• Activity of CHS 828 in primary cultures of human hematological and solidtumors in vitro. (2001)
• Antitumor effect of suramin analogues in human tumour cell lines and primary cultures of tumour cells (2000)
• Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine (2000)
• Cellular cytotoxic drug sensitivity in children with leukemia and Down´s syndrome: an explanation differences in clinical outcome? (2000)
• Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. (2000)
• Differential activity of topotecan, irinotecan and SN-38 in primary cultures of human tumor cells but not in cell lines. (2000)
• Determination of drug effect on tumor cells, host animal toxicity and drug pharmacokinetics in a hollow fiber model in rats. (2000)
• Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB. (2000)
• Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients (2000)
• Ex vivo activity of cytotoxic drugs and targeted agents in Small Intestinal NETs
• Paired glioblastoma cell cultures of the fluorescent bulk tumor and non-fluorescent tumor margin display differential phenotypes and cell states across patients
• Drug combination screening in multicellular tumor spheroids identifies synthetic lethalities in quiescent cancer cells

Konferenser

• Hemocompatibility of Nanocellulose Polypyrrole Membranes Intended for Hemodialysis (2012)